Amorphous Idelalisib Preparation via Solvent Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing Idelalisib result in low yield and impurity issues, particularly with polymorphic forms and chromatographic purity, making them unsuitable for industrial scale-up.
Innovation Solution
A process involving specific reactions and solvents to produce Idelalisib, including reacting compounds in halogenated hydrocarbon solvents, treating with 2-amino-6-fluoro-benzoic acid, Diphenylphosphine, and pyridine, followed by deprotection and purification steps using ammonia and aqueous alcohol, to achieve high purity and amorphous form.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the process according to WO 2005/1 13556 A1 is used to prepare Idelalisib, then the product can be obtained, but the yield is low and purity is insufficient
Solution Approach 1:
The patent changes the physical state parameter of the product from crystalline to amorphous form, and modifies reaction parameters such as using different solvents (DMF, DCM, MeOH) and reagents (DIPEA instead of traditional bases) to achieve both high purity (>99.7% chromatographic purity) and improved yield (72-78%) while eliminating polymorphic form issues
Solution Approach 2:
The patent deliberately induces phase transition from crystalline to amorphous form by controlling the drying process and solvent removal conditions. The amorphous form is obtained by dissolving the crude product in minimal DMF and concentrating under reduced pressure at controlled temperature (40-50°C), which prevents crystallization and yields a stable amorphous solid with superior purity and yield characteristics
2Reliability
If the process according to WO 2005/1 13556 A1 is used, then Idelalisib can be produced, but polymorphic form issues arise and purity is compromised
Solution Approach 1:
The patent changes the physical state parameter from crystalline to amorphous form, which eliminates polymorphic form issues entirely. The amorphous Idelalisib is obtained through controlled solvent removal from DMF solution at 40-50°C under reduced pressure, creating a stable amorphous solid that shows no polymorphic transitions and achieves >99.7% chromatographic purity
Solution Approach 2:
The patent uses common, readily available solvents and reagents (DMF, DCM, MeOH, DIPEA, EDCI, HOBt) that are easy to handle and remove, avoiding the need for specialized equipment or complex purification procedures. The process uses standard laboratory materials to achieve high reliability and purity
3Manufacturing precision
If column chromatography is used to purify the crude product, then some purification is achieved, but the process is complex and not suitable for industrial scale-up
Solution Approach 1:
The patent extracts and removes impurities through simple filtration steps during the reaction sequence. The final product is obtained by dissolving the crude material in minimal DMF and concentrating under reduced pressure, which automatically purifies the product without requiring column chromatography. This extraction-based approach achieves >99.7% purity while maintaining process simplicity for industrial scale-up
Solution Approach 2:
The reaction conditions and workup procedures are designed to self-purify the product. The selective chemistry of the coupling reactions, combined with the solubility differences in the chosen solvents (DMF, DCM, MeOH), allows impurities to remain in solution or be easily filtered off, while the product crystallizes or precipitates in pure form, eliminating the need for complex chromatographic purification
Data Source
AI summary
The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.